A 36-week, Randomized, Double-blind, Multi-center, Parallel Group Study Comparing the Efficacy and Safety of Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension.
Phase of Trial: Phase III
Latest Information Update: 03 Feb 2015
At a glance
- Drugs Aliskiren (Primary) ; Losartan
- Indications Essential hypertension; Hypertension; Left ventricular hypertrophy
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms ALLAY; ASPIRE-HIGHER
- Sponsors Novartis
- 09 May 2011 Additional trial locations (Argentina, Colombia, Finland, Italy, Russia, Spain, Sweden) added as reported by ClinicalTrials.gov
- 15 Jun 2009 Pharmcodynamic results presented at the 19th European Meeting on Hypertension, 2009.
- 03 Feb 2009 Resulted reported in Circulation, 3 February 2009.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History